Home › Valeant misses expectations as loses $89 million in Q4, $116M for full year
 

Keywords :   


Valeant misses expectations as loses $89 million in Q4, $116M for full year

2013-02-28 23:56:10| Biotech - Topix.net

Valeant Pharmaceuticals International missed expectations as it net loss grew in the fourth-quarter and full-year amid higher operating expenses and items related to restructuring and acquisitions.

Tags: year full million expectations

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.10Hurricane Milton Potential Storm Surge Flooding Map
07.10Hurricane Milton Probabilistic Storm Surge Graphics
07.10Hurricane Milton Graphics
07.10Hurricane Leslie Forecast Discussion Number 19
07.10Hurricane Milton Forecast Discussion Number 7
07.10Hurricane Milton Wind Speed Probabilities Number 7
07.10Hurricane Leslie Graphics
07.10Hurricane Milton Forecast Advisory Number 7
More »